Literature DB >> 11310945

Preference for fractures and other glucocorticoid-associated adverse effects among rheumatoid arthritis patients.

L A Merlino1, I Bagchi, T N Taylor, P Utrie, E Chrischilles, W Sumner, A Mudano, K G Saag.   

Abstract

OBJECTIVE: The objective of this study was to determine rheumatoid arthritis (RA) patients' preferences for validated health state scenarios depicting glucocorticoid adverse events, predictors of these preferences, and psychometric properties of different preference techniques in this population.
METHODS: Preferences were elicited by rating scale and time trade-off methods. Time trade-offs included trading current health for either time spent alive in an adverse health state for chronic conditions (time trade-off) or time spent in a sleeplike state for acute conditions (sleep trade-off).
RESULTS: A total of 107 subjects with long-standing RA participated in the preference interviews. Mean preference values (rating scale/trade-off) were lowest for serious fracture adverse events, including hip fracture requiring a nursing home stay (0.55+/-0.22/0.76+/-0.36) and vertebral fracture with chronic pain (0.59+/-0.23/0.67+/-0.35), and highest for cataracts (0.84 + 0.17/0.96 0.09) and wrist fracture (0.82+/-0.18/0.81+/-0.29). Rating scales had a stronger correlation (r= 0.88) with physician ranking of scenarios than trade-off methods (r = 0.31). All methods were feasible and demonstrated good reliability, while rating scale method showed better construct validity than trade-off techniques.
CONCLUSION: Relative to their current health, RA patients assigned low preference values to many glucocorticoid adverse events, particularly those associated with chronic fracture outcomes. Results varied with the preference measure used, indicating that methodological attributes of preference determinations must be considered in clinical decision making.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11310945     DOI: 10.1177/0272989X0102100205

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  14 in total

Review 1.  A descriptive review on methods to prioritize outcomes in a health care context.

Authors:  Inger M Janssen; Ansgar Gerhardus; Milly A Schröer-Günther; Fülöp Scheibler
Journal:  Health Expect       Date:  2014-08-25       Impact factor: 3.377

2.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

Review 3.  Methods for measuring temporary health States for cost-utility analyses.

Authors:  Davene R Wright; Eve Wittenberg; J Shannon Swan; Rebecca A Miksad; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

4.  Time Trade-off Utility Values in Noninfectious Uveitis.

Authors:  Katherine M Niemeyer; John A Gonzales; Thuy Doan; Erica N Browne; Maya M Rao; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2019-06-13       Impact factor: 5.258

5.  The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.

Authors:  F Borgström; A Carlsson; H Sintonen; S Boonen; P Haentjens; R Burge; O Johnell; B Jönsson; J A Kanis
Journal:  Osteoporos Int       Date:  2006-03-29       Impact factor: 4.507

6.  The risk and burden of vertebral fractures in Sweden.

Authors:  J A Kanis; O Johnell; A Oden; F Borgstrom; N Zethraeus; C De Laet; B Jonsson
Journal:  Osteoporos Int       Date:  2003-10-31       Impact factor: 4.507

7.  Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden.

Authors:  John A Kanis; Olof Johnell; Anders Oden; Frederik Borgstrom; Helena Johansson; Chris De Laet; Bengt Jönsson
Journal:  Osteoporos Int       Date:  2004-04-22       Impact factor: 4.507

8.  Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.

Authors:  T Beukelman; K G Saag; J R Curtis; M L Kilgore; M Pisu
Journal:  Osteoporos Int       Date:  2009-11-24       Impact factor: 4.507

Review 9.  An updated systematic review of Health State Utility Values for osteoporosis related conditions.

Authors:  T Peasgood; K Herrmann; J A Kanis; J E Brazier
Journal:  Osteoporos Int       Date:  2009-03-07       Impact factor: 4.507

Review 10.  Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women.

Authors:  J A Kanis; F Borgstrom; O Johnell; B Jonsson
Journal:  Osteoporos Int       Date:  2004-06-03       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.